m6A modification: recent advances, anticancer targeted drug discovery and beyond

Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platfo...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 21; no. 1; pp. 52 - 21
Main Authors Deng, Li-Juan, Deng, Wei-Qing, Fan, Shu-Ran, Chen, Min-Feng, Qi, Ming, Lyu, Wen-Yu, Qi, Qi, Tiwari, Amit K., Chen, Jia-Xu, Zhang, Dong-Mei, Chen, Zhe-Sheng
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 14.02.2022
BioMed Central
BMC
Subjects
Adenosine - chemistry
Antineoplastic drugs
Antitumor agents
Apoptosis
Artificial Intelligence
Binding sites
Cancer
Chemosynthesis
Drug delivery
Drug Discovery
Drug resistance
Gene expression
Humans
Intellectual disabilities
m6A
Medical prognosis
Metastasis
Methyltransferases
Modulators
N6-methyladenosine
Natural product
Natural products
Neoplasms - drug therapy
Neoplasms - genetics
Prognosis
Proteins
Review
Therapeutic targets
Traditional medicine
Tumors
Natural product
m6A
Chemosynthesis
Drug discovery
Modulators
Cancer
Online AccessGet full text

Cover

Abstract Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Graphical abstract Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.
AbstractList Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs.
Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.
Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.
Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Graphical abstract Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future. Keywords: m6A, Cancer, Modulators, Drug discovery, Natural product, Chemosynthesis
Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Graphical abstract Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.
Abstract Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-related approaches and modern drug discovery platforms have been used in an attempt to develop m6A-targeted drugs. Here, we provide an update of the latest findings on m6A modification and the critical roles of m6A modification in cancer progression, and we summarize rational sources for the discovery of m6A-targeted anticancer agents from traditional medicines and computer-based chemosynthetic compounds. This review highlights the potential agents targeting m6A modification for cancer treatment and proposes the advantage of artificial intelligence (AI) in the discovery of m6A-targeting anticancer drugs. Graphical abstract Three stages of m6A-targeting anticancer drug discovery: traditional medicine-based natural products, modern chemical modification or synthesis, and artificial intelligence (AI)-assisted approaches for the future.
ArticleNumber 52
Audience Academic
Author Qi, Qi
Lyu, Wen-Yu
Tiwari, Amit K.
Chen, Jia-Xu
Chen, Zhe-Sheng
Zhang, Dong-Mei
Deng, Li-Juan
Deng, Wei-Qing
Qi, Ming
Chen, Min-Feng
Fan, Shu-Ran
Author_xml – sequence: 1
  givenname: Li-Juan
  surname: Deng
  fullname: Deng, Li-Juan
– sequence: 2
  givenname: Wei-Qing
  surname: Deng
  fullname: Deng, Wei-Qing
– sequence: 3
  givenname: Shu-Ran
  surname: Fan
  fullname: Fan, Shu-Ran
– sequence: 4
  givenname: Min-Feng
  surname: Chen
  fullname: Chen, Min-Feng
– sequence: 5
  givenname: Ming
  surname: Qi
  fullname: Qi, Ming
– sequence: 6
  givenname: Wen-Yu
  surname: Lyu
  fullname: Lyu, Wen-Yu
– sequence: 7
  givenname: Qi
  surname: Qi
  fullname: Qi, Qi
– sequence: 8
  givenname: Amit K.
  surname: Tiwari
  fullname: Tiwari, Amit K.
– sequence: 9
  givenname: Jia-Xu
  surname: Chen
  fullname: Chen, Jia-Xu
– sequence: 10
  givenname: Dong-Mei
  surname: Zhang
  fullname: Zhang, Dong-Mei
– sequence: 11
  givenname: Zhe-Sheng
  orcidid: 0000-0002-8289-097X
  surname: Chen
  fullname: Chen, Zhe-Sheng
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35164788$$D View this record in MEDLINE/PubMed
BookMark eNp9kk1r3DAQhk1JaT7aP9BDMfTSQ51KsiTLPQSW0I9AoD20ZzGWRlsttpXK3sD--87upks2lKKDxOiZV_OK97w4GdOIRfGas0vOjf4wcdHKumJCVIwrzirxrDjjstGVVK05eXQ-Lc6nacUYb0wjXxSnteJaNsacFd8HvSiH5GOIDuaYxo9lRofjXIK_h9Hh9L6EcaZLOudyhrzEGX3p83pZ-ji5dI95Q4gvO9yk0b8sngfoJ3z1sF8UPz9_-nH9tbr99uXmenFbOaXruYJOGG2g6YRShgZjgnEZgvPIQEvlGAhRCymDrKEJID0K5TWEVpumkQj1RXGz1_UJVvYuxwHyxiaIdldIeWkh09w9WqW4YkGgYR1KYBoU7zx3rEYE1yAnrau91t26G9Bv7Wfoj0SPb8b4yy7TvTVG0vwNCbx7EMjp9xqn2Q70Ndj3MGJaT1Zo0TIyqhShb5-gq7TOI30VUTVTUivaD9QSyEAcQ6J33VbULnTbKs34jrr8B0XL4xAdhSVEqh81vHls9ODwbx4IEHvA5TRNGcMB4cxuQ2f3obMUOrsLnRXUZJ40uTjvwkTjxP5_rX8A6bfZQg
CitedBy_id crossref_primary_10_1038_s41416_023_02246_6
crossref_primary_10_3389_fimmu_2023_1281687
crossref_primary_10_1038_s41392_024_01956_4
crossref_primary_10_1016_j_biopha_2023_115477
crossref_primary_10_1016_j_lfs_2024_122922
crossref_primary_10_1016_j_archoralbio_2024_105979
crossref_primary_10_1016_j_biopha_2024_116966
crossref_primary_10_1016_j_exer_2023_109489
crossref_primary_10_1186_s40364_022_00410_3
crossref_primary_10_1002_ijc_35067
crossref_primary_10_1093_jpp_rgae108
crossref_primary_10_1016_j_bioorg_2023_106477
crossref_primary_10_1111_acel_14123
crossref_primary_10_1007_s40726_023_00278_3
crossref_primary_10_1186_s12943_023_01848_1
crossref_primary_10_1136_gutjnl_2023_330459
crossref_primary_10_1038_s41598_024_75033_9
crossref_primary_10_1016_j_drup_2024_101063
crossref_primary_10_1088_1361_6560_ad6951
crossref_primary_10_1186_s12935_024_03240_5
crossref_primary_10_1093_cei_uxae025
crossref_primary_10_1038_s41598_024_64517_3
crossref_primary_10_1038_s41420_023_01580_1
crossref_primary_10_1016_j_bbcan_2023_188961
crossref_primary_10_1186_s12943_022_01620_x
crossref_primary_10_1093_nar_gkac801
crossref_primary_10_1186_s12967_024_05293_6
crossref_primary_10_1186_s13046_024_03095_8
crossref_primary_10_1016_j_phymed_2023_155316
crossref_primary_10_1186_s12967_024_05330_4
crossref_primary_10_1515_med_2023_0856
crossref_primary_10_62347_IDCP2061
crossref_primary_10_1016_j_cellsig_2024_111420
crossref_primary_10_7868_S0032874X23120086
crossref_primary_10_1186_s12964_023_01401_z
crossref_primary_10_2147_IJN_S380697
crossref_primary_10_3390_pharmaceutics17010121
crossref_primary_10_1016_j_ejmech_2023_115802
crossref_primary_10_3389_fimmu_2023_1256691
crossref_primary_10_1016_j_bbrep_2023_101572
crossref_primary_10_1038_s41392_022_01175_9
crossref_primary_10_1002_mco2_559
crossref_primary_10_1186_s13046_024_03035_6
crossref_primary_10_3389_fendo_2022_972341
crossref_primary_10_1016_j_ijbiomac_2025_141588
crossref_primary_10_1002_advs_202305142
crossref_primary_10_3389_fpubh_2022_914193
crossref_primary_10_3389_fimmu_2024_1494873
crossref_primary_10_1186_s12575_024_00245_2
crossref_primary_10_1097_HC9_0000000000000046
crossref_primary_10_3389_fimmu_2024_1469435
crossref_primary_10_1186_s40001_023_01382_2
crossref_primary_10_1111_jcmm_17577
crossref_primary_10_1093_lifemedi_lnad008
crossref_primary_10_1038_s41585_023_00851_x
crossref_primary_10_1038_s42003_023_04929_5
crossref_primary_10_1016_j_clbc_2023_04_007
crossref_primary_10_1016_j_pbiomolbio_2024_10_003
crossref_primary_10_1039_D4CB00215F
crossref_primary_10_1007_s12033_023_00843_7
crossref_primary_10_1007_s12672_024_01023_y
crossref_primary_10_3389_fonc_2022_1074307
crossref_primary_10_3389_fonc_2024_1387444
crossref_primary_10_1002_wrna_1810
crossref_primary_10_1016_j_gendis_2025_101567
crossref_primary_10_1093_bfgp_elae020
crossref_primary_10_1016_j_jacbts_2024_01_017
crossref_primary_10_1016_j_cellsig_2024_111076
crossref_primary_10_1016_j_heliyon_2023_e19816
crossref_primary_10_3389_fimmu_2024_1453774
crossref_primary_10_1016_j_phrs_2023_106863
crossref_primary_10_1186_s12964_023_01148_7
crossref_primary_10_3389_fphar_2023_1149777
crossref_primary_10_1002_advs_202403412
crossref_primary_10_1038_s41417_024_00791_7
crossref_primary_10_1002_advs_202307928
crossref_primary_10_1016_j_intimp_2024_113079
crossref_primary_10_1038_s41420_024_01988_3
crossref_primary_10_1016_j_bbagrm_2023_194967
crossref_primary_10_1186_s12943_022_01704_8
crossref_primary_10_1021_acs_jmedchem_3c01374
crossref_primary_10_62347_LXOS2662
crossref_primary_10_1016_j_medj_2023_09_001
crossref_primary_10_1186_s13148_023_01586_7
crossref_primary_10_1007_s40495_023_00345_9
crossref_primary_10_1021_acschemneuro_4c00620
crossref_primary_10_1016_j_molmed_2023_03_005
crossref_primary_10_1002_med_22079
crossref_primary_10_3389_fmolb_2023_1163089
crossref_primary_10_1186_s12943_023_01810_1
crossref_primary_10_1002_advs_202307242
crossref_primary_10_1002_ctm2_1337
crossref_primary_10_1016_j_lfs_2024_122644
crossref_primary_10_1002_art_42676
crossref_primary_10_3233_CBM_230188
crossref_primary_10_1093_carcin_bgad016
crossref_primary_10_1186_s12943_023_01724_y
crossref_primary_10_1002_ctm2_1460
crossref_primary_10_1002_ijc_34378
crossref_primary_10_1016_j_pharmthera_2023_108576
crossref_primary_10_1111_cas_16381
crossref_primary_10_1007_s11427_024_2707_9
crossref_primary_10_1016_j_isci_2025_111989
crossref_primary_10_1038_s41417_024_00781_9
crossref_primary_10_1002_pul2_12230
crossref_primary_10_1016_j_ijbiomac_2024_139150
crossref_primary_10_3390_ijms232213851
crossref_primary_10_31083_j_fbl2903120
crossref_primary_10_3389_fgene_2022_974740
crossref_primary_10_1038_s41598_025_93062_w
crossref_primary_10_1111_cas_16136
crossref_primary_10_1016_j_expneurol_2024_114948
crossref_primary_10_1111_cpr_13294
crossref_primary_10_1186_s13046_024_03136_2
crossref_primary_10_2147_BCTT_S481549
crossref_primary_10_31083_j_fbl2711304
crossref_primary_10_14336_AD_2023_0924_1
crossref_primary_10_1080_15384047_2024_2349429
crossref_primary_10_3390_biom12091224
crossref_primary_10_1016_j_gendis_2023_03_016
crossref_primary_10_1007_s13402_024_01016_7
crossref_primary_10_1093_postmj_qgae105
crossref_primary_10_1186_s12885_023_11741_1
crossref_primary_10_1186_s13062_024_00566_y
crossref_primary_10_3389_fimmu_2025_1556764
crossref_primary_10_1007_s12672_023_00759_3
crossref_primary_10_3390_biology14010061
crossref_primary_10_1038_s41598_023_39506_7
crossref_primary_10_1016_j_gde_2024_102206
crossref_primary_10_3390_biom13020243
crossref_primary_10_1007_s10495_023_01817_5
crossref_primary_10_18632_aging_205768
crossref_primary_10_3892_ijo_2023_5605
crossref_primary_10_1016_j_bbamcr_2024_119716
crossref_primary_10_3390_app14188391
crossref_primary_10_1007_s11010_024_05040_x
crossref_primary_10_3390_brainsci13091311
crossref_primary_10_1186_s12964_024_01980_5
crossref_primary_10_1615_CritRevEukaryotGeneExpr_2023048801
crossref_primary_10_1016_j_jbiotec_2024_12_013
crossref_primary_10_3389_fcimb_2022_972655
crossref_primary_10_1016_j_lfs_2024_123146
crossref_primary_10_1016_j_canlet_2024_216735
crossref_primary_10_1007_s12013_024_01331_8
crossref_primary_10_1111_exd_14696
crossref_primary_10_3390_ijms242115585
crossref_primary_10_1016_j_jdermsci_2024_01_001
crossref_primary_10_1038_s41467_024_45675_4
crossref_primary_10_1186_s12876_023_03065_y
crossref_primary_10_1016_j_snb_2025_137494
crossref_primary_10_1016_j_biopha_2023_115719
crossref_primary_10_1007_s11684_024_1064_8
crossref_primary_10_1038_s41380_023_02339_x
crossref_primary_10_1126_sciadv_add0960
crossref_primary_10_1016_j_biopha_2023_114343
crossref_primary_10_1002_mco2_70135
crossref_primary_10_1016_j_biopha_2024_116922
crossref_primary_10_1002_mco2_546
crossref_primary_10_3892_ijo_2024_5674
crossref_primary_10_1002_mco2_787
crossref_primary_10_1002_1878_0261_13326
crossref_primary_10_1007_s43032_023_01271_3
crossref_primary_10_1016_j_gene_2025_149222
crossref_primary_10_1096_fj_202301419RR
crossref_primary_10_1016_j_jbc_2023_104677
crossref_primary_10_3389_fimmu_2022_997316
crossref_primary_10_1002_ctm2_1405
crossref_primary_10_3389_fgene_2025_1522622
crossref_primary_10_3389_fimmu_2023_1122317
crossref_primary_10_1007_s11684_023_1052_4
crossref_primary_10_1016_j_ijbiomac_2024_134212
crossref_primary_10_1186_s12935_023_02955_1
crossref_primary_10_3389_fonc_2022_895315
crossref_primary_10_1186_s13048_022_01058_1
crossref_primary_10_1186_s13046_023_02732_y
crossref_primary_10_3389_fendo_2023_1166756
crossref_primary_10_1016_j_pbiomolbio_2024_12_003
crossref_primary_10_1016_j_neo_2023_100912
crossref_primary_10_1002_advs_202309840
crossref_primary_10_3389_fphar_2024_1351929
crossref_primary_10_1002_ibra_12183
crossref_primary_10_34133_research_0340
crossref_primary_10_1186_s12967_025_06139_5
crossref_primary_10_2147_CMAR_S391067
crossref_primary_10_1093_bib_bbad498
crossref_primary_10_1038_s41417_023_00628_9
crossref_primary_10_3389_fonc_2022_939790
crossref_primary_10_1016_j_biocel_2023_106502
crossref_primary_10_1016_j_tibs_2024_01_003
crossref_primary_10_3390_cells12172179
crossref_primary_10_1016_j_drudis_2023_103875
crossref_primary_10_1038_s41392_024_01826_z
crossref_primary_10_3390_ijms24086905
crossref_primary_10_3390_genes14010086
crossref_primary_10_1186_s12943_024_01979_z
crossref_primary_10_1016_j_heliyon_2024_e24963
crossref_primary_10_1038_s41388_024_02992_8
crossref_primary_10_1038_s12276_024_01184_4
crossref_primary_10_1093_mr_roae080
crossref_primary_10_1111_jcmm_70344
crossref_primary_10_1186_s12943_024_02132_6
crossref_primary_10_1007_s12032_024_02402_9
crossref_primary_10_1016_j_biopha_2023_115524
crossref_primary_10_1016_j_biopha_2023_114669
crossref_primary_10_1007_s12033_024_01250_2
crossref_primary_10_3389_fonc_2022_970833
crossref_primary_10_1007_s00210_024_02961_8
crossref_primary_10_1155_2022_9744771
Cites_doi 10.1038/srep42271
10.1002/cmdc.202000011
10.1016/j.ccell.2017.02.013
10.1038/s41419-020-03315-x
10.1016/j.stem.2019.03.021
10.1093/bib/bbz157
10.7554/eLife.31311
10.1021/acs.jnatprod.9b01285
10.2147/OTT.S226796
10.1186/s12943-019-1106-z
10.1016/j.molcel.2012.10.015
10.1039/C4SC02554G
10.1186/s12943-020-01267-6
10.1002/cmdc.202100291
10.1186/s12943-020-01158-w
10.1126/science.1151710
10.1016/j.cmet.2021.04.001
10.1038/s41556-018-0045-z
10.1158/0008-5472.CAN-21-0494
10.1038/s41366-018-0082-5
10.1016/j.molcel.2018.07.025
10.1021/acs.jafc.9b00037
10.1186/s12943-020-01220-7
10.1038/s41388-020-1338-9
10.1074/jbc.M116.749689
10.1186/s12943-019-1108-x
10.15252/embr.202052146
10.1016/j.celrep.2019.06.072
10.1016/j.omto.2021.05.003
10.1186/s12943-019-1079-y
10.1038/s41419-021-03558-2
10.7150/thno.55424
10.1016/j.celrep.2019.02.100
10.1002/1878-0261.12676
10.1093/nar/gkaa048
10.1186/s13045-019-0839-x
10.1073/pnas.2025948118
10.1021/jacs.5b06690
10.1093/nar/gky1012
10.1186/1758-2946-6-13
10.7150/thno.51342
10.1002/ctm2.602
10.1016/j.apsb.2021.08.015
10.1186/s12943-019-1036-9
10.1038/cr.2014.3
10.1038/s41392-020-00453-8
10.1038/s41418-021-00804-0
10.1016/j.ebiom.2020.102955
10.1186/s13059-021-02271-9
10.1039/C8FO02004C
10.1038/nature14234
10.1186/s12943-021-01340-8
10.1016/j.ymben.2017.06.005
10.1016/j.bmc.2019.115300
10.1016/j.cell.2015.05.014
10.2147/DDDT.S291865
10.1038/s41422-018-0113-8
10.1016/j.drup.2020.100720
10.1016/j.stem.2017.11.016
10.1002/hep.31766
10.1016/j.phymed.2018.09.174
10.1186/s12943-021-01359-x
10.7150/jca.42338
10.1038/s41576-020-00295-8
10.1186/s13046-020-01731-7
10.1186/s12943-019-1038-7
10.1038/nm.4416
10.1186/s13045-021-01124-z
10.1186/s12943-020-1146-4
10.1016/j.canlet.2021.07.015
10.1186/s12943-020-01190-w
10.1038/s41388-019-0683-z
10.1186/s12943-019-1082-3
10.1038/s41422-019-0270-4
10.1111/jcmm.15736
10.1186/s12943-019-1084-1
10.1021/acsomega.9b02236
10.3389/fonc.2020.01166
10.1038/s41422-020-00397-2
10.1007/s13105-019-00690-8
10.7150/thno.40144
10.1002/cac2.12075
10.1186/s12943-019-1088-x
10.7150/thno.20657
10.1038/s41467-019-12801-6
10.1002/jmr.2800
10.1038/s41467-019-10669-0
10.18632/oncotarget.22868
10.1038/s41392-020-00450-x
10.1186/s12943-020-01239-w
10.1186/s12943-019-1128-6
10.1038/s41586-021-03536-w
10.1038/s41467-019-09712-x
10.7150/thno.55574
10.1093/nar/gku1276
10.15252/embj.2019103181
10.1038/nature19342
10.1158/0008-5472.CAN-20-0066
10.1016/j.cell.2015.08.011
10.1021/jm400193d
10.1039/D0NP00043D
10.1038/s41419-019-1470-z
10.15252/embj.2020105977
10.1186/s13059-021-02308-z
10.1186/s13046-019-1408-4
10.1038/s41418-019-0461-z
10.1186/s12943-019-1065-4
10.1038/s41419-020-03049-w
10.1016/j.omtn.2021.06.005
10.1186/s12943-019-1053-8
10.1002/jmr.2606
10.1021/acs.analchem.0c02828
10.1002/jcp.29645
10.1080/15592294.2020.1788324
10.1186/s13046-021-02072-9
10.1007/s12257-020-0049-y
10.1038/nature12730
10.1021/acs.molpharmaceut.8b00522
10.1016/j.canlet.2017.11.018
10.1021/ja3064149
10.1073/pnas.1521518113
10.1038/nchembio.1432
10.1038/s41467-020-20527-z
10.1038/s12276-020-00510-w
10.1016/j.ymthe.2020.06.024
10.1038/s41388-019-0861-z
10.1186/s12943-020-01204-7
10.1016/j.cell.2020.05.012
10.1016/j.molcel.2021.06.014
10.1038/s41419-019-1585-2
10.1016/j.molcel.2016.01.012
10.1016/j.phrs.2020.105387
10.1002/anie.202103854
10.1016/j.stem.2020.04.009
10.1186/s13045-019-0830-6
10.15252/embj.2020104514
10.1186/s13045-017-0507-y
10.1016/j.cell.2017.11.031
10.1021/acsomega.1c01289
10.1002/hep.29683
10.1515/CCLM.2005.187
10.1016/j.ymthe.2020.09.007
10.1021/acsmedchemlett.1c00102
10.7150/ijbs.45886
10.1016/j.redox.2020.101801
10.1038/cr.2017.99
10.1002/hep.31222
10.1016/j.omtn.2020.10.031
10.1038/nature24678
10.1038/cr.2017.15
10.1016/j.canlet.2018.11.006
10.1016/j.pharmthera.2020.107686
10.3389/fonc.2019.00332
10.7150/thno.51231
10.1053/j.gastro.2020.11.013
10.1186/s13046-021-01857-2
10.1158/0008-5472.CAN-19-4044
10.1038/s41389-020-00290-y
10.3389/fonc.2021.716921
10.1186/s13046-020-01714-8
10.1038/s41467-020-20379-7
10.1002/1878-0261.12898
10.1158/0008-5472.CAN-20-1619
10.1186/s12943-020-01223-4
10.1038/s41598-018-22631-z
10.1038/onc.2017.351
10.1186/s12943-019-1119-7
10.1186/s13046-021-01871-4
10.1016/j.ejmech.2020.112325
10.1016/j.ymthe.2021.12.012
10.1186/s13045-021-01066-6
10.1007/s10895-017-2086-2
10.1038/s41419-020-02847-6
10.1128/aem.62.11.4039-4043.1996
10.1038/171344a0
10.1016/j.ccell.2020.04.017
10.1002/med.21565
10.1016/j.celrep.2017.02.059
10.1186/s12943-020-01249-8
10.2147/OTT.S205730
10.1021/acs.chemrev.8b00728
10.1093/nar/gkz1147
10.1186/s12943-019-1004-4
10.1038/s41421-018-0019-0
10.1093/nar/gkx1182
10.1111/jcmm.15228
10.1186/s13045-020-00872-8
10.1002/hep.28885
10.1016/j.molcel.2016.03.021
10.1038/s41388-020-01638-9
10.1016/j.ymthe.2020.03.010
10.1016/j.ccell.2019.03.006
10.1038/d41573-019-00179-5
10.1016/j.omtn.2020.01.033
10.1016/j.drudis.2020.10.010
10.1038/s41467-019-11552-8
10.1016/j.drudis.2020.03.003
10.1038/s41586-018-0538-8
10.1016/j.ccell.2020.10.004
10.1038/s41467-020-15403-9
10.1073/pnas.2000516117
10.1038/s41556-018-0174-4
10.1126/scitranslmed.aau7116
10.1016/j.molcel.2018.02.015
10.1038/s41419-018-1224-3
10.1016/j.ymthe.2019.11.016
10.1186/s13045-021-01123-0
10.1038/s41416-021-01581-w
10.1021/acschembio.0c00841
10.1016/j.ccell.2016.11.017
10.1093/nar/gkab378
10.1158/0008-5472.CAN-18-2868
10.1002/wrna.1681
10.1093/nar/gkz619
10.1136/gutjnl-2019-319639
10.1038/s41417-020-00222-3
ContentType Journal Article
Copyright 2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2022
Copyright_xml – notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2022
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12943-022-01510-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Medical Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content (ProQuest)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Publicly Available Content Database

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 21
ExternalDocumentID oai_doaj_org_article_55150f2e80be4a06a51bd1c03eeac7e1
PMC8842557
A699560126
35164788
10_1186_s12943_022_01510_2
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 2020A1515011090
– fundername: ;
  grantid: 81803790; 81630104; 81973340; 81803566
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PMFND
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c563t-ab2868a7b255800102014ffcde0a645c0a223244f43a7fa4de25d6af968774ea3
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:30:05 EDT 2025
Thu Aug 21 18:10:58 EDT 2025
Sun Aug 24 04:16:12 EDT 2025
Fri Jul 25 20:59:06 EDT 2025
Tue Jun 17 21:27:36 EDT 2025
Tue Jun 10 20:15:01 EDT 2025
Mon Jul 21 05:45:50 EDT 2025
Tue Jul 01 01:01:19 EDT 2025
Thu Apr 24 22:51:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Natural product
m6A
Chemosynthesis
Drug discovery
Modulators
Cancer
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-ab2868a7b255800102014ffcde0a645c0a223244f43a7fa4de25d6af968774ea3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8289-097X
OpenAccessLink https://doaj.org/article/55150f2e80be4a06a51bd1c03eeac7e1
PMID 35164788
PQID 2630546526
PQPubID 42702
PageCount 21
ParticipantIDs doaj_primary_oai_doaj_org_article_55150f2e80be4a06a51bd1c03eeac7e1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8842557
proquest_miscellaneous_2629055855
proquest_journals_2630546526
gale_infotracmisc_A699560126
gale_infotracacademiconefile_A699560126
pubmed_primary_35164788
crossref_primary_10_1186_s12943_022_01510_2
crossref_citationtrail_10_1186_s12943_022_01510_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-02-14
PublicationDateYYYYMMDD 2022-02-14
PublicationDate_xml – month: 02
  year: 2022
  text: 2022-02-14
  day: 14
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2022
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References J Zhou (1510_CR62) 2017; 10
X Zuo (1510_CR110) 2020; 13
L Ma (1510_CR174) 2021; 38
L Lan (1510_CR217) 2021; 60
D Jin (1510_CR132) 2019; 12
D Paul (1510_CR220) 2021; 26
T Li (1510_CR80) 2019; 18
HL Huang (1510_CR43) 2018; 20
B Chen (1510_CR189) 2012; 134
X Yang (1510_CR51) 2020; 19
L Wang (1510_CR85) 2020; 39
R Pinto (1510_CR28) 2020; 48
Y Niu (1510_CR68) 2019; 18
B Li (1510_CR134) 2021; 12
X Chen (1510_CR84) 2020; 19
R Miao (1510_CR105) 2020; 235
C Shen (1510_CR60) 2020; 27
PJ Hsu (1510_CR42) 2017; 27
D Zhou (1510_CR169) 2021; 15
X Wang (1510_CR126) 2021; 40
S Selberg (1510_CR209) 2021; 6
H Yu (1510_CR175) 2021; 23
SM Peng (1510_CR207) 2019; 11
Z Gan (1510_CR178) 2019; 4
F Peng (1510_CR52) 2021; 31
PM Ueland (1510_CR184) 2005; 43
JX Zhao (1510_CR53) 2021; 16
T Lan (1510_CR114) 2019; 18
J Li (1510_CR38) 2020; 19
J Zhang (1510_CR151) 2019; 10
W Miao (1510_CR212) 2019; 10
Z Yang (1510_CR92) 2020; 39
F Xie (1510_CR77) 2021; 20
1510_CR15
Q Cui (1510_CR97) 2017; 18
KA Doxtader (1510_CR26) 2018; 71
J Yu (1510_CR190) 2018; 46
J Hou (1510_CR120) 2019; 18
M Cully (1510_CR8) 2019; 18
S Zhu (1510_CR90) 2020; 11
S Muller (1510_CR147) 2019; 47
BM Edens (1510_CR44) 2019; 28
S Zhuang (1510_CR188) 2019; 67
1510_CR106
V Tassinari (1510_CR95) 2021; 22
Y Chen (1510_CR113) 2019; 18
1510_CR20
I Barbieri (1510_CR54) 2017; 552
P Zhu (1510_CR72) 2021; 40
CW Bacon (1510_CR193) 1996; 62
X Wang (1510_CR35) 2015; 161
EV Moroz-Omori (1510_CR216) 2021; 16
Y Jiang (1510_CR145) 2020; 24
RC Chai (1510_CR171) 2021; 14
JC Zhong (1510_CR14) 2020; 18
C Gu (1510_CR76) 2019; 18
1510_CR27
T Wang (1510_CR2) 2020; 19
X-L Ping (1510_CR22) 2014; 24
Y Bai (1510_CR87) 2019; 9
W Peng (1510_CR78) 2019; 38
R Jia (1510_CR138) 2019; 18
JZ Ma (1510_CR112) 2017; 65
X Cai (1510_CR63) 2018; 415
S Zaccara (1510_CR34) 2020; 181
Y Huang (1510_CR202) 2019; 35
N Liu (1510_CR48) 2015; 518
D Wiener (1510_CR1) 2021; 22
C Yue (1510_CR86) 2020; 39
X Liu (1510_CR65) 2020; 28
F Xu (1510_CR146) 2021; 20
P Wu (1510_CR122) 2021; 12
Y Zhao (1510_CR6) 2020; 13
A Visvanathan (1510_CR96) 2018; 37
Q Li (1510_CR117) 2021; 6
S Chen (1510_CR149) 2020; 11
T Gerken (1510_CR31) 2007; 318
Y Xu (1510_CR69) 2020; 40
T Su (1510_CR118) 2021; 74
BJ Petri (1510_CR73) 2021; 518
J Ru (1510_CR221) 2014; 6
N Ding (1510_CR214) 2020; 16
Y Shi (1510_CR136) 2019; 10
RW Sabnis (1510_CR210) 2021; 12
Z Li (1510_CR57) 2017; 31
V Miranda-Goncalves (1510_CR165) 2021; 40
S Yang (1510_CR137) 2019; 10
K Mohanraj (1510_CR222) 2018; 8
J Gu (1510_CR7) 2020; 196
1510_CR140
C Zhou (1510_CR172) 2020; 59
L Zhang (1510_CR12) 2020; 216
JJ Lu (1510_CR10) 2020; 18
M Cheng (1510_CR75) 2019; 38
S D'Souza (1510_CR19) 2020; 25
JDW Toh (1510_CR206) 2015; 6
J Liu (1510_CR93) 2018; 20
E Yankova (1510_CR9) 2021; 593
J Han (1510_CR74) 2019; 18
X Li (1510_CR191) 2018; 50
JY Qian (1510_CR71) 2019; 38
H Wang (1510_CR131) 2019; 18
W Xiao (1510_CR41) 2016; 61
L Zhu (1510_CR100) 2019; 10
Y Yuan (1510_CR150) 2021; 12
R Zhang (1510_CR18) 2021; 38
HL Shi (1510_CR39) 2017; 27
T Ghazi (1510_CR194) 2021; 16
RY Wang (1510_CR196) 2018; 15
YT Sun (1510_CR101) 2020; 11
JM Einstein (1510_CR37) 2021; 81
F Zhang (1510_CR45) 2018; 27
J Choe (1510_CR46) 2018; 561
J Cai (1510_CR159) 2019; 12
H Weng (1510_CR56) 2018; 22
T Ren (1510_CR187) 2017; 27
X Huang (1510_CR197) 2017; 42
DJ Newman (1510_CR218) 2020; 83
Y Ban (1510_CR121) 2020; 14
N Van Tran (1510_CR29) 2019; 47
IA Roundtree (1510_CR40) 2017; 6
H Kim (1510_CR16) 2020; 25
1510_CR88
Y Huang (1510_CR200) 2015; 43
T Liu (1510_CR148) 2020; 48
S Oerum (1510_CR5) 2021; 49
N Yao (1510_CR13) 2019; 10
S Zhang (1510_CR98) 2017; 31
JJ He (1510_CR128) 2020; 10
W Aik (1510_CR205) 2013; 56
R Fang (1510_CR99) 2021; 12
JW Xie (1510_CR103) 2020; 19
H Huang (1510_CR144) 2020; 80
Y Chen (1510_CR116) 2020; 19
WW Chen (1510_CR198) 2020; 24
A Malacrida (1510_CR211) 2020; 28
Z Chen (1510_CR135) 2020; 28
J Wen (1510_CR25) 2018; 69
S Selberg (1510_CR213) 2019; 26
Y Zhang (1510_CR4) 2021; 22
C Zhang (1510_CR167) 2016; 113
P Zhang (1510_CR123) 2018; 9
S Lin (1510_CR133) 2016; 62
RK Bedi (1510_CR215) 2020; 15
Y Xiao (1510_CR163) 2020; 117
Y Hou (1510_CR157) 2021; 28
T Sun (1510_CR166) 2020; 39
B Tang (1510_CR156) 2020; 19
J Paris (1510_CR61) 2019; 25
X Qian (1510_CR130) 2021; 14
J Pi (1510_CR108) 2021; 81
LP Vu (1510_CR55) 2017; 23
C Zhang (1510_CR162) 2021; 11
X Bi (1510_CR142) 2021; 28
W Zhao (1510_CR124) 2020; 20
L Cheng (1510_CR64) 2021; 10
S Huff (1510_CR204) 2021; 16
A Lewinska (1510_CR199) 2017; 7
B Li (1510_CR50) 2020; 53
GQ Zheng (1510_CR32) 2013; 49
K Sun (1510_CR192) 2021; 11
Y Gu (1510_CR164) 2021; 81
1510_CR176
H Chen (1510_CR30) 2020; 30
1510_CR179
Y Yuan (1510_CR160) 2020; 11
M Bagherian (1510_CR17) 2021; 22
J Zeng (1510_CR154) 2021; 25
P Hou (1510_CR91) 2021; 40
X Pan (1510_CR66) 2021; 53
W Lai (1510_CR182) 2018; 9
AP Singh (1510_CR177) 2019; 39
S Singh (1510_CR181) 2021; 164
DP Patil (1510_CR23) 2016; 537
X Liu (1510_CR115) 2020; 72
F Jiang (1510_CR141) 2021; 14
Y Liu (1510_CR203) 2021; 33
R Su (1510_CR58) 2018; 172
X Wang (1510_CR36) 2014; 505
Z Lin (1510_CR168) 2020; 39
C Chen (1510_CR82) 2021; 11
R Wu (1510_CR49) 2019; 29
F Li (1510_CR94) 2019; 79
H Zhang (1510_CR161) 2020; 24
Y Yue (1510_CR24) 2018; 4
X Hu (1510_CR158) 2020; 27
R Wu (1510_CR183) 2018; 42
HL Yu (1510_CR143) 2019; 12
CR Alarcón (1510_CR47) 2015; 162
G Chang (1510_CR70) 2020; 38
X Guo (1510_CR155) 2020; 19
W Ni (1510_CR89) 2019; 18
J Deng (1510_CR153) 2021; 81
Y Zhang (1510_CR208) 2020; 92
H Chen (1510_CR79) 2021; 160
J Ye (1510_CR129) 2020; 10
C Shen (1510_CR81) 2020; 19
L Zhong (1510_CR173) 2019; 442
Y Wang (1510_CR186) 2019; 32
X Yang (1510_CR219) 2019; 119
Z Yang (1510_CR119) 2017; 292
J Liu (1510_CR21) 2014; 10
J Zhang (1510_CR107) 2019; 75
P Delmotte (1510_CR195) 1953; 171
T Wang (1510_CR201) 2015; 137
X Chen (1510_CR83) 2020; 28
W Xu (1510_CR180) 2021; 15
X Jiang (1510_CR3) 2021; 6
Z Yang (1510_CR170) 2021; 118
F Zhu (1510_CR127) 2021; 11
YR Leng (1510_CR11) 2021; 19
R Su (1510_CR59) 2020; 38
B Yue (1510_CR104) 2019; 18
L Zhang (1510_CR185) 2019; 10
Y Ueda (1510_CR33) 2017; 7
ZJ Chen (1510_CR67) 2020; 10
M Wang (1510_CR152) 2020; 19
L Liu (1510_CR125) 2020; 28
J Yu (1510_CR139) 2021; 22
M Chen (1510_CR111) 2018; 67
L Liu (1510_CR109) 2019; 18
Q Wang (1510_CR102) 2020; 69
References_xml – volume: 7
  start-page: 42271
  year: 2017
  ident: 1510_CR33
  publication-title: Sci Rep
  doi: 10.1038/srep42271
– volume: 15
  start-page: 744
  year: 2020
  ident: 1510_CR215
  publication-title: ChemMedChem.
  doi: 10.1002/cmdc.202000011
– volume: 31
  start-page: 591
  year: 2017
  ident: 1510_CR98
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2017.02.013
– volume: 12
  start-page: 60
  year: 2021
  ident: 1510_CR150
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-03315-x
– volume: 25
  start-page: 137
  year: 2019
  ident: 1510_CR61
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2019.03.021
– volume: 22
  start-page: 247
  year: 2021
  ident: 1510_CR17
  publication-title: Brief Bioinform
  doi: 10.1093/bib/bbz157
– volume: 6
  start-page: e31311
  year: 2017
  ident: 1510_CR40
  publication-title: Elife.
  doi: 10.7554/eLife.31311
– volume: 83
  start-page: 770
  year: 2020
  ident: 1510_CR218
  publication-title: J Nat Prod
  doi: 10.1021/acs.jnatprod.9b01285
– volume: 12
  start-page: 9143
  year: 2019
  ident: 1510_CR159
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S226796
– volume: 18
  start-page: 186
  year: 2019
  ident: 1510_CR114
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1106-z
– volume: 49
  start-page: 18
  year: 2013
  ident: 1510_CR32
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2012.10.015
– volume: 6
  start-page: 112
  year: 2015
  ident: 1510_CR206
  publication-title: Chem Sci
  doi: 10.1039/C4SC02554G
– volume: 19
  start-page: 152
  year: 2020
  ident: 1510_CR38
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01267-6
– volume: 16
  start-page: 3035
  year: 2021
  ident: 1510_CR216
  publication-title: ChemMedChem.
  doi: 10.1002/cmdc.202100291
– volume: 19
  start-page: 91
  year: 2020
  ident: 1510_CR155
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01158-w
– volume: 318
  start-page: 1469
  year: 2007
  ident: 1510_CR31
  publication-title: Science.
  doi: 10.1126/science.1151710
– volume: 33
  start-page: 1221
  year: 2021
  ident: 1510_CR203
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2021.04.001
– volume: 20
  start-page: 285
  year: 2018
  ident: 1510_CR43
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0045-z
– volume: 81
  start-page: 5268
  year: 2021
  ident: 1510_CR153
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-21-0494
– volume: 42
  start-page: 1378
  year: 2018
  ident: 1510_CR183
  publication-title: Int J Obes
  doi: 10.1038/s41366-018-0082-5
– volume: 71
  start-page: 1001
  year: 2018
  ident: 1510_CR26
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2018.07.025
– volume: 67
  start-page: 2519
  year: 2019
  ident: 1510_CR188
  publication-title: J Agric Food Chem
  doi: 10.1021/acs.jafc.9b00037
– volume: 19
  start-page: 106
  year: 2020
  ident: 1510_CR84
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01220-7
– volume: 39
  start-page: 5358
  year: 2020
  ident: 1510_CR166
  publication-title: Oncogene.
  doi: 10.1038/s41388-020-1338-9
– volume: 292
  start-page: 3614
  year: 2017
  ident: 1510_CR119
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M116.749689
– volume: 18
  start-page: 181
  year: 2019
  ident: 1510_CR131
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1108-x
– ident: 1510_CR176
  doi: 10.15252/embr.202052146
– volume: 28
  start-page: 845
  year: 2019
  ident: 1510_CR44
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2019.06.072
– volume: 22
  start-page: 52
  year: 2021
  ident: 1510_CR4
  publication-title: Mol Ther Oncolytics
  doi: 10.1016/j.omto.2021.05.003
– volume: 18
  start-page: 143
  year: 2019
  ident: 1510_CR89
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1079-y
– volume: 12
  start-page: 298
  year: 2021
  ident: 1510_CR122
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03558-2
– volume: 18
  start-page: 696
  year: 2020
  ident: 1510_CR14
  publication-title: Chin J Nat Med
– volume: 11
  start-page: 3676
  year: 2021
  ident: 1510_CR162
  publication-title: Theranostics.
  doi: 10.7150/thno.55424
– volume: 26
  start-page: 3762
  year: 2019
  ident: 1510_CR213
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2019.02.100
– volume: 14
  start-page: 1282
  year: 2020
  ident: 1510_CR121
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12676
– volume: 48
  start-page: 3816
  year: 2020
  ident: 1510_CR148
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkaa048
– volume: 13
  start-page: 5
  year: 2020
  ident: 1510_CR110
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-019-0839-x
– volume: 118
  start-page: e2025948118
  year: 2021
  ident: 1510_CR170
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.2025948118
– volume: 137
  start-page: 13736
  year: 2015
  ident: 1510_CR201
  publication-title: J Am Chem Soc
  doi: 10.1021/jacs.5b06690
– volume: 47
  start-page: 375
  year: 2019
  ident: 1510_CR147
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gky1012
– volume: 6
  start-page: 13
  year: 2014
  ident: 1510_CR221
  publication-title: J Cheminform
  doi: 10.1186/1758-2946-6-13
– volume: 11
  start-page: 4298
  year: 2021
  ident: 1510_CR82
  publication-title: Theranostics.
  doi: 10.7150/thno.51342
– ident: 1510_CR88
  doi: 10.1002/ctm2.602
– ident: 1510_CR15
  doi: 10.1016/j.apsb.2021.08.015
– volume: 18
  start-page: 110
  year: 2019
  ident: 1510_CR74
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1036-9
– volume: 24
  start-page: 177
  year: 2014
  ident: 1510_CR22
  publication-title: Cell Res
  doi: 10.1038/cr.2014.3
– volume: 6
  start-page: 76
  year: 2021
  ident: 1510_CR117
  publication-title: Signal Transduct Tar
  doi: 10.1038/s41392-020-00453-8
– volume: 28
  start-page: 3105
  year: 2021
  ident: 1510_CR157
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-021-00804-0
– volume: 59
  start-page: 102955
  year: 2020
  ident: 1510_CR172
  publication-title: EBioMedicine.
  doi: 10.1016/j.ebiom.2020.102955
– volume: 22
  start-page: 51
  year: 2021
  ident: 1510_CR95
  publication-title: Genome Biol
  doi: 10.1186/s13059-021-02271-9
– volume: 10
  start-page: 216
  year: 2019
  ident: 1510_CR185
  publication-title: Food Funct
  doi: 10.1039/C8FO02004C
– volume: 518
  start-page: 560
  year: 2015
  ident: 1510_CR48
  publication-title: Nature.
  doi: 10.1038/nature14234
– volume: 20
  start-page: 45
  year: 2021
  ident: 1510_CR146
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01340-8
– volume: 42
  start-page: 109
  year: 2017
  ident: 1510_CR197
  publication-title: Metab Eng
  doi: 10.1016/j.ymben.2017.06.005
– volume: 28
  start-page: 115300
  year: 2020
  ident: 1510_CR211
  publication-title: Bioorg Med Chem
  doi: 10.1016/j.bmc.2019.115300
– volume: 161
  start-page: 1388
  year: 2015
  ident: 1510_CR35
  publication-title: Cell.
  doi: 10.1016/j.cell.2015.05.014
– volume: 27
  start-page: 3936
  year: 2018
  ident: 1510_CR45
  publication-title: Hum Mol Genet
– volume: 15
  start-page: 577
  year: 2021
  ident: 1510_CR180
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT.S291865
– volume: 29
  start-page: 23
  year: 2019
  ident: 1510_CR49
  publication-title: Cell Res
  doi: 10.1038/s41422-018-0113-8
– volume: 53
  start-page: 100720
  year: 2020
  ident: 1510_CR50
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2020.100720
– volume: 22
  start-page: 191
  year: 2018
  ident: 1510_CR56
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2017.11.016
– volume: 74
  start-page: 1339
  year: 2021
  ident: 1510_CR118
  publication-title: Hepatology.
  doi: 10.1002/hep.31766
– volume: 50
  start-page: 73
  year: 2018
  ident: 1510_CR191
  publication-title: Phytomedicine.
  doi: 10.1016/j.phymed.2018.09.174
– volume: 20
  start-page: 68
  year: 2021
  ident: 1510_CR77
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01359-x
– volume: 11
  start-page: 3588
  year: 2020
  ident: 1510_CR160
  publication-title: J Cancer
  doi: 10.7150/jca.42338
– volume: 22
  start-page: 119
  year: 2021
  ident: 1510_CR1
  publication-title: Nat Rev Genet
  doi: 10.1038/s41576-020-00295-8
– volume: 39
  start-page: 240
  year: 2020
  ident: 1510_CR86
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-020-01731-7
– volume: 18
  start-page: 481
  year: 2020
  ident: 1510_CR10
  publication-title: Chin J Nat Med
– volume: 18
  start-page: 112
  year: 2019
  ident: 1510_CR80
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1038-7
– volume: 23
  start-page: 1369
  year: 2017
  ident: 1510_CR55
  publication-title: Nat Med
  doi: 10.1038/nm.4416
– volume: 14
  start-page: 109
  year: 2021
  ident: 1510_CR171
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01124-z
– volume: 19
  start-page: 12
  year: 2021
  ident: 1510_CR11
  publication-title: Chin J Nat Med
– volume: 19
  start-page: 46
  year: 2020
  ident: 1510_CR51
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-1146-4
– volume: 518
  start-page: 152
  year: 2021
  ident: 1510_CR73
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2021.07.015
– volume: 19
  start-page: 72
  year: 2020
  ident: 1510_CR81
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01190-w
– volume: 38
  start-page: 3667
  year: 2019
  ident: 1510_CR75
  publication-title: Oncogene.
  doi: 10.1038/s41388-019-0683-z
– volume: 18
  start-page: 163
  year: 2019
  ident: 1510_CR120
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1082-3
– volume: 30
  start-page: 544
  year: 2020
  ident: 1510_CR30
  publication-title: Cell Res
  doi: 10.1038/s41422-019-0270-4
– volume: 24
  start-page: 12368
  year: 2020
  ident: 1510_CR161
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.15736
– volume: 18
  start-page: 168
  year: 2019
  ident: 1510_CR76
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1084-1
– volume: 4
  start-page: 17438
  year: 2019
  ident: 1510_CR178
  publication-title: ACS Omega
  doi: 10.1021/acsomega.9b02236
– volume: 10
  start-page: 1166
  year: 2020
  ident: 1510_CR128
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.01166
– volume: 31
  start-page: 345
  year: 2021
  ident: 1510_CR52
  publication-title: Cell Res
  doi: 10.1038/s41422-020-00397-2
– volume: 75
  start-page: 379
  year: 2019
  ident: 1510_CR107
  publication-title: J Physiol Biochem
  doi: 10.1007/s13105-019-00690-8
– volume: 10
  start-page: 3382
  year: 2020
  ident: 1510_CR67
  publication-title: Theranostics.
  doi: 10.7150/thno.40144
– volume: 40
  start-page: 484
  year: 2020
  ident: 1510_CR69
  publication-title: Cancer Commun (Lond)
  doi: 10.1002/cac2.12075
– volume: 18
  start-page: 161
  year: 2019
  ident: 1510_CR138
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1088-x
– volume: 7
  start-page: 3461
  year: 2017
  ident: 1510_CR199
  publication-title: Theranostics.
  doi: 10.7150/thno.20657
– volume: 10
  start-page: 4892
  year: 2019
  ident: 1510_CR136
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-12801-6
– volume: 32
  start-page: e2800
  year: 2019
  ident: 1510_CR186
  publication-title: J Mol Recognit
  doi: 10.1002/jmr.2800
– volume: 10
  start-page: 2782
  year: 2019
  ident: 1510_CR137
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-10669-0
– volume: 9
  start-page: 901
  year: 2018
  ident: 1510_CR182
  publication-title: Oncotarget.
  doi: 10.18632/oncotarget.22868
– volume: 6
  start-page: 74
  year: 2021
  ident: 1510_CR3
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00450-x
– volume: 19
  start-page: 123
  year: 2020
  ident: 1510_CR116
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01239-w
– volume: 19
  start-page: 3
  year: 2020
  ident: 1510_CR156
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1128-6
– volume: 593
  start-page: 597
  year: 2021
  ident: 1510_CR9
  publication-title: Nature.
  doi: 10.1038/s41586-021-03536-w
– volume: 10
  start-page: 1858
  year: 2019
  ident: 1510_CR151
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-09712-x
– volume: 11
  start-page: 5831
  year: 2021
  ident: 1510_CR192
  publication-title: Theranostics.
  doi: 10.7150/thno.55574
– volume: 43
  start-page: 373
  year: 2015
  ident: 1510_CR200
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku1276
– volume: 39
  start-page: e103181
  year: 2020
  ident: 1510_CR168
  publication-title: EMBO J
  doi: 10.15252/embj.2019103181
– volume: 537
  start-page: 369
  year: 2016
  ident: 1510_CR23
  publication-title: Nature.
  doi: 10.1038/nature19342
– volume: 81
  start-page: 2651
  year: 2021
  ident: 1510_CR108
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-20-0066
– volume: 162
  start-page: 1299
  year: 2015
  ident: 1510_CR47
  publication-title: Cell.
  doi: 10.1016/j.cell.2015.08.011
– volume: 56
  start-page: 3680
  year: 2013
  ident: 1510_CR205
  publication-title: J Med Chem
  doi: 10.1021/jm400193d
– volume: 38
  start-page: 346
  year: 2021
  ident: 1510_CR18
  publication-title: Nat Prod Rep
  doi: 10.1039/D0NP00043D
– volume: 10
  start-page: 232
  year: 2019
  ident: 1510_CR13
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-1470-z
– ident: 1510_CR20
  doi: 10.15252/embj.2020105977
– volume: 22
  start-page: 85
  year: 2021
  ident: 1510_CR139
  publication-title: Genome Biol
  doi: 10.1186/s13059-021-02308-z
– volume: 38
  start-page: 393
  year: 2019
  ident: 1510_CR78
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-019-1408-4
– volume: 27
  start-page: 1782
  year: 2020
  ident: 1510_CR158
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-019-0461-z
– volume: 18
  start-page: 142
  year: 2019
  ident: 1510_CR104
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1065-4
– volume: 11
  start-page: 836
  year: 2020
  ident: 1510_CR101
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-03049-w
– volume: 25
  start-page: 277
  year: 2021
  ident: 1510_CR154
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2021.06.005
– volume: 18
  start-page: 127
  year: 2019
  ident: 1510_CR113
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1053-8
– ident: 1510_CR179
  doi: 10.1002/jmr.2606
– volume: 92
  start-page: 13936
  year: 2020
  ident: 1510_CR208
  publication-title: Anal Chem
  doi: 10.1021/acs.analchem.0c02828
– volume: 235
  start-page: 7420
  year: 2020
  ident: 1510_CR105
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.29645
– volume: 16
  start-page: 79
  year: 2021
  ident: 1510_CR194
  publication-title: Epigenetics.
  doi: 10.1080/15592294.2020.1788324
– volume: 40
  start-page: 268
  year: 2021
  ident: 1510_CR165
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-02072-9
– volume: 25
  start-page: 895
  year: 2020
  ident: 1510_CR16
  publication-title: Biotechnol Bioprocess Eng
  doi: 10.1007/s12257-020-0049-y
– volume: 505
  start-page: 117
  year: 2014
  ident: 1510_CR36
  publication-title: Nature.
  doi: 10.1038/nature12730
– volume: 15
  start-page: 4092
  year: 2018
  ident: 1510_CR196
  publication-title: Mol Pharm
  doi: 10.1021/acs.molpharmaceut.8b00522
– volume: 415
  start-page: 11
  year: 2018
  ident: 1510_CR63
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.11.018
– volume: 134
  start-page: 17963
  year: 2012
  ident: 1510_CR189
  publication-title: J Am Chem Soc
  doi: 10.1021/ja3064149
– volume: 113
  start-page: E2047
  year: 2016
  ident: 1510_CR167
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1521518113
– volume: 10
  start-page: 93
  year: 2014
  ident: 1510_CR21
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.1432
– volume: 12
  start-page: 295
  year: 2021
  ident: 1510_CR134
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-20527-z
– volume: 53
  start-page: 91
  year: 2021
  ident: 1510_CR66
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-020-00510-w
– volume: 28
  start-page: 2177
  year: 2020
  ident: 1510_CR125
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.06.024
– volume: 38
  start-page: 6123
  year: 2019
  ident: 1510_CR71
  publication-title: Oncogene.
  doi: 10.1038/s41388-019-0861-z
– volume: 19
  start-page: 88
  year: 2020
  ident: 1510_CR2
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01204-7
– volume: 181
  start-page: 1582
  year: 2020
  ident: 1510_CR34
  publication-title: Cell.
  doi: 10.1016/j.cell.2020.05.012
– volume: 81
  start-page: 3048
  year: 2021
  ident: 1510_CR37
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2021.06.014
– volume: 10
  start-page: 383
  year: 2019
  ident: 1510_CR100
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-1585-2
– volume: 61
  start-page: 507
  year: 2016
  ident: 1510_CR41
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2016.01.012
– volume: 164
  start-page: 105387
  year: 2021
  ident: 1510_CR181
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2020.105387
– volume: 60
  start-page: 18116
  year: 2021
  ident: 1510_CR217
  publication-title: Angew Chem Int Ed Eng
  doi: 10.1002/anie.202103854
– volume: 27
  start-page: 64
  year: 2020
  ident: 1510_CR60
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2020.04.009
– volume: 12
  start-page: 135
  year: 2019
  ident: 1510_CR132
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-019-0830-6
– volume: 16
  start-page: 363
  year: 2021
  ident: 1510_CR53
  publication-title: Recent Pat Anti Canc
– volume: 39
  start-page: e104514
  year: 2020
  ident: 1510_CR85
  publication-title: EMBO J
  doi: 10.15252/embj.2020104514
– volume: 10
  start-page: 138
  year: 2017
  ident: 1510_CR62
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-017-0507-y
– volume: 172
  start-page: 90
  year: 2018
  ident: 1510_CR58
  publication-title: Cell.
  doi: 10.1016/j.cell.2017.11.031
– volume: 6
  start-page: 13310
  year: 2021
  ident: 1510_CR209
  publication-title: ACS Omega
  doi: 10.1021/acsomega.1c01289
– volume: 67
  start-page: 2254
  year: 2018
  ident: 1510_CR111
  publication-title: Hepatology.
  doi: 10.1002/hep.29683
– volume: 43
  start-page: 1069
  year: 2005
  ident: 1510_CR184
  publication-title: Clin Chem Lab Med
  doi: 10.1515/CCLM.2005.187
– volume: 28
  start-page: 2593
  year: 2020
  ident: 1510_CR65
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.09.007
– volume: 12
  start-page: 856
  year: 2021
  ident: 1510_CR210
  publication-title: ACS Med Chem Lett
  doi: 10.1021/acsmedchemlett.1c00102
– volume: 16
  start-page: 2595
  year: 2020
  ident: 1510_CR214
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.45886
– volume: 38
  start-page: 101801
  year: 2021
  ident: 1510_CR174
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2020.101801
– volume: 27
  start-page: 1115
  year: 2017
  ident: 1510_CR42
  publication-title: Cell Res
  doi: 10.1038/cr.2017.99
– volume: 72
  start-page: 2029
  year: 2020
  ident: 1510_CR115
  publication-title: Hepatology.
  doi: 10.1002/hep.31222
– volume: 23
  start-page: 27
  year: 2021
  ident: 1510_CR175
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2020.10.031
– volume: 552
  start-page: 126
  year: 2017
  ident: 1510_CR54
  publication-title: Nature.
  doi: 10.1038/nature24678
– volume: 27
  start-page: 315
  year: 2017
  ident: 1510_CR39
  publication-title: Cell Res
  doi: 10.1038/cr.2017.15
– volume: 24
  start-page: 4263
  year: 2020
  ident: 1510_CR198
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 442
  start-page: 252
  year: 2019
  ident: 1510_CR173
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2018.11.006
– volume: 216
  start-page: 107686
  year: 2020
  ident: 1510_CR12
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2020.107686
– volume: 9
  start-page: 332
  year: 2019
  ident: 1510_CR87
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00332
– volume: 10
  start-page: 12072
  year: 2020
  ident: 1510_CR129
  publication-title: Theranostics.
  doi: 10.7150/thno.51231
– volume: 160
  start-page: 1284
  year: 2021
  ident: 1510_CR79
  publication-title: Gastroenterology.
  doi: 10.1053/j.gastro.2020.11.013
– volume: 40
  start-page: 52
  year: 2021
  ident: 1510_CR91
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-01857-2
– volume: 80
  start-page: 3200
  year: 2020
  ident: 1510_CR144
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-4044
– volume: 10
  start-page: 7
  year: 2021
  ident: 1510_CR64
  publication-title: Oncogenesis.
  doi: 10.1038/s41389-020-00290-y
– volume: 11
  start-page: 716921
  year: 2021
  ident: 1510_CR127
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.716921
– volume: 39
  start-page: 203
  year: 2020
  ident: 1510_CR92
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-020-01714-8
– volume: 12
  start-page: 177
  year: 2021
  ident: 1510_CR99
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-20379-7
– volume: 15
  start-page: 2172
  year: 2021
  ident: 1510_CR169
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12898
– volume: 81
  start-page: 923
  year: 2021
  ident: 1510_CR164
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-20-1619
– volume: 19
  start-page: 114
  year: 2020
  ident: 1510_CR103
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01223-4
– volume: 8
  start-page: 4329
  year: 2018
  ident: 1510_CR222
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-22631-z
– volume: 37
  start-page: 522
  year: 2018
  ident: 1510_CR96
  publication-title: Oncogene.
  doi: 10.1038/onc.2017.351
– volume: 18
  start-page: 188
  year: 2019
  ident: 1510_CR109
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1119-7
– volume: 40
  start-page: 80
  year: 2021
  ident: 1510_CR126
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-01871-4
– volume: 196
  start-page: 112325
  year: 2020
  ident: 1510_CR7
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2020.112325
– ident: 1510_CR140
  doi: 10.1016/j.ymthe.2021.12.012
– volume: 14
  start-page: 54
  year: 2021
  ident: 1510_CR141
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01066-6
– volume: 27
  start-page: 1467
  year: 2017
  ident: 1510_CR187
  publication-title: J Fluoresc
  doi: 10.1007/s10895-017-2086-2
– volume: 11
  start-page: 659
  year: 2020
  ident: 1510_CR149
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-020-02847-6
– volume: 62
  start-page: 4039
  year: 1996
  ident: 1510_CR193
  publication-title: Appl Environ Microbiol
  doi: 10.1128/aem.62.11.4039-4043.1996
– volume: 171
  start-page: 344
  year: 1953
  ident: 1510_CR195
  publication-title: Nature.
  doi: 10.1038/171344a0
– volume: 38
  start-page: 79
  year: 2020
  ident: 1510_CR59
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.04.017
– volume: 39
  start-page: 1851
  year: 2019
  ident: 1510_CR177
  publication-title: Med Res Rev
  doi: 10.1002/med.21565
– volume: 18
  start-page: 2622
  year: 2017
  ident: 1510_CR97
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.02.059
– volume: 19
  start-page: 130
  year: 2020
  ident: 1510_CR152
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01249-8
– volume: 12
  start-page: 6191
  year: 2019
  ident: 1510_CR143
  publication-title: Oncotargets Ther
  doi: 10.2147/OTT.S205730
– volume: 119
  start-page: 10520
  year: 2019
  ident: 1510_CR219
  publication-title: Chem Rev
  doi: 10.1021/acs.chemrev.8b00728
– volume: 48
  start-page: 830
  year: 2020
  ident: 1510_CR28
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz1147
– volume: 18
  start-page: 46
  year: 2019
  ident: 1510_CR68
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1004-4
– volume: 4
  start-page: 10
  year: 2018
  ident: 1510_CR24
  publication-title: Cell Discov
  doi: 10.1038/s41421-018-0019-0
– volume: 46
  start-page: 1412
  year: 2018
  ident: 1510_CR190
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1182
– volume: 24
  start-page: 6137
  year: 2020
  ident: 1510_CR145
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.15228
– volume: 13
  start-page: 35
  year: 2020
  ident: 1510_CR6
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00872-8
– volume: 65
  start-page: 529
  year: 2017
  ident: 1510_CR112
  publication-title: Hepatology.
  doi: 10.1002/hep.28885
– volume: 62
  start-page: 335
  year: 2016
  ident: 1510_CR133
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2016.03.021
– volume: 40
  start-page: 1609
  year: 2021
  ident: 1510_CR72
  publication-title: Oncogene.
  doi: 10.1038/s41388-020-01638-9
– volume: 28
  start-page: 1479
  year: 2020
  ident: 1510_CR135
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.03.010
– volume: 35
  start-page: 677
  year: 2019
  ident: 1510_CR202
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.03.006
– volume: 18
  start-page: 892
  year: 2019
  ident: 1510_CR8
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/d41573-019-00179-5
– volume: 20
  start-page: 1
  year: 2020
  ident: 1510_CR124
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2020.01.033
– volume: 26
  start-page: 80
  year: 2021
  ident: 1510_CR220
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2020.10.010
– volume: 10
  start-page: 3613
  year: 2019
  ident: 1510_CR212
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-11552-8
– volume: 25
  start-page: 748
  year: 2020
  ident: 1510_CR19
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2020.03.003
– volume: 561
  start-page: 556
  year: 2018
  ident: 1510_CR46
  publication-title: Nature.
  doi: 10.1038/s41586-018-0538-8
– volume: 38
  start-page: 857
  year: 2020
  ident: 1510_CR70
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.10.004
– volume: 11
  start-page: 1685
  year: 2020
  ident: 1510_CR90
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-15403-9
– volume: 117
  start-page: 21441
  year: 2020
  ident: 1510_CR163
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.2000516117
– volume: 20
  start-page: 1074
  year: 2018
  ident: 1510_CR93
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0174-4
– volume: 11
  start-page: eaau7116
  year: 2019
  ident: 1510_CR207
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aau7116
– volume: 69
  start-page: 1028
  year: 2018
  ident: 1510_CR25
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2018.02.015
– volume: 9
  start-page: 1169
  year: 2018
  ident: 1510_CR123
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-1224-3
– volume: 28
  start-page: 599
  year: 2020
  ident: 1510_CR83
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2019.11.016
– volume: 14
  start-page: 112
  year: 2021
  ident: 1510_CR130
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-021-01123-0
– ident: 1510_CR106
  doi: 10.1038/s41416-021-01581-w
– volume: 16
  start-page: 324
  year: 2021
  ident: 1510_CR204
  publication-title: ACS Chem Biol
  doi: 10.1021/acschembio.0c00841
– volume: 31
  start-page: 127
  year: 2017
  ident: 1510_CR57
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.11.017
– volume: 49
  start-page: 7239
  year: 2021
  ident: 1510_CR5
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkab378
– volume: 79
  start-page: 5785
  year: 2019
  ident: 1510_CR94
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-18-2868
– ident: 1510_CR27
  doi: 10.1002/wrna.1681
– volume: 47
  start-page: 7719
  year: 2019
  ident: 1510_CR29
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz619
– volume: 69
  start-page: 1193
  year: 2020
  ident: 1510_CR102
  publication-title: Gut.
  doi: 10.1136/gutjnl-2019-319639
– volume: 28
  start-page: 335
  year: 2021
  ident: 1510_CR142
  publication-title: Cancer Gene Ther
  doi: 10.1038/s41417-020-00222-3
SSID ssj0017874
Score 2.678585
SecondaryResourceType review_article
Snippet Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A...
Abstract Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 52
SubjectTerms Adenosine - chemistry
Antineoplastic drugs
Antitumor agents
Apoptosis
Artificial Intelligence
Binding sites
Cancer
Chemosynthesis
Drug delivery
Drug Discovery
Drug resistance
Gene expression
Humans
Intellectual disabilities
m6A
Medical prognosis
Metastasis
Methyltransferases
Modulators
N6-methyladenosine
Natural product
Natural products
Neoplasms - drug therapy
Neoplasms - genetics
Prognosis
Proteins
Review
Therapeutic targets
Traditional medicine
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KIKWXkqYvt2lQodBDa2LLkiznti0JoZDSQwO5CVmPtpB4yz4O-feZkbXLmkJ76dUaGevTPDSehwDe1SH2vInoptq2L0VEn7WnH_kx-DZEH5vgyFG8_KoursSXa3m9c9UX5YSN7YFH4E7Qossq8qCrPghbKSvr3teuagKqjDYkxwdt3saZyvEDZEOxKZHR6mSJVk1QvJLSEJALSz4xQ6lb_586eccoTRMmdyzQ-QE8zkdHNhs_-Qk8CMMh7I-XSd4dwsPLHCZ_Ct9u1Yzdzj2lASXkTxkqNnwryyH_5UeGiJIGdGHBxmzw4JlfrH8wqtOlvM47JPGsTxUuz-Dq_Oz754syX51QOqmaVWl7rpVG-NFj0KlvHLpCMTofKquEdJXldJQSUTS2jVb4wKVXNnZK43kw2OY57A3zIbwEFnljfa0jyq4XLnado1CeUNaHVljXFVBvkDQu9xWn6y1uTPIvtDIj-gbRNwl9wwv4sJ3ze-yq8VfqT7RBW0rqiJ0eIJ-YzCfmX3xSwHvaXkNyi5_nbC4_wEVSBywzU1Tji-ZaFXA0oUR5c9PhDYOYLO9LwxXqTaEkDb_dDtNMymEbwnxNNLyrcDukLODFyE_bJTWS-rppXUA74bTJmqcjw6-fqRu4pkCqbF_9D5BewyOehISXtTiCvdViHd7goWvVHyf5ugddpigv
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1La9ZAcNCK4kW0vqJVIggeNDTZ7G42XuRTLEWoeLDw3ZbNPlrBJvV7HPrvndnsFxuEXrOTkJ337MzOALytfOhYHTBMNU1X8IAxa0cH-cG7xgcXam8pUDz5Lo9P-belWKYDt3Uqq9zpxKio3WDpjPyQSeRMLgWTny7_FDQ1irKraYTGbbhDrcuopKtZTgFXhczIdxdllDxco23jlLWkYgTkxYLNjFHs2f-_Zr5mmuZlk9fs0NFDeJAcyHwxUvwR3PL9PtwdR0pe7cO9k5Qsfww_LuQivxgcFQNF_H_MUb3hV_OU-F9_yBGvpAetX-VjTbh3uVttz3K6rUvVnVcI4vIu3nN5AqdHX39-OS7SAIXCCllvCtMxJRUSAeMGFbvHYUAUgnW-NJILWxpGDhUPvDZNMNx5Jpw0oZUKvUJv6qew1w-9fw55YLVxlQoowY7b0LaWEnpcGucbbmybQbXDpLapuzgNufitY5ShpB6xrxH7OmJfswzeT-9cjr01boT-TASaIKkvdnwwrM50EjON_p8oA_Oq7Dw3pTSi6lxly9qjgWl8lcE7Iq8m6cXfsyZdQsBNUh8svZB00xeNtszgYAaJUmfnyzsG0Unq1_ofj2bwZlqmN6mSrffDlmBYWyI5hMjg2chP05ZqQd3dlMqgmXHabM_zlf7XeewJriidKpoXN__WS7jPIvuzouIHsLdZbf0rdKo23esoOX8BYCIfDA
  priority: 102
  providerName: ProQuest
Title m6A modification: recent advances, anticancer targeted drug discovery and beyond
URI https://www.ncbi.nlm.nih.gov/pubmed/35164788
https://www.proquest.com/docview/2630546526
https://www.proquest.com/docview/2629055855
https://pubmed.ncbi.nlm.nih.gov/PMC8842557
https://doaj.org/article/55150f2e80be4a06a51bd1c03eeac7e1
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ra9RAcKgtln4RrY9G6xFB8INGk83uJieIXKWlHFwp6sF9Wzb7qEJ7V-8B3r93ZpNcG6x-OsjOhtudd-YF8DpzvmK5RzdVF1XCPfqsFX3I984WzlufO0OO4uhMno75cCImW9COO2oucHGna0fzpMbzy_e_f60_I8N_Cgxfyg8L1FmcopGUZIA0lqBI3kHNVBCjjvhNVAGJk7eFM3fu24PdXFCHrTCI5UZPhXb-fwvtW1qrm1F5S0WdPIQHjW0ZD2pieARbbroP9-tpk-t92B01cfTHcH4lB_HVzFKeUEDNxxglH741bnICFu9ivHISkcbN4zpd3NnYzlcXMRXyUuLnGkFsXIUSmCcwPjn-_uU0aWYrJEbIfJnoipWyRPygS1GGxnLoK3lvrEu15MKkmpGtxT3PdeE1t44JK7XvyxINRqfzp7A9nU3dAcSe5dpmpUfmttz4ft9QrI9LbV3BtelHkLU3qUzTeJzmX1yq4ICUUtWIUIgIFRChWARvN3uu67Yb_4U-IgRtIKlldngwm1-ohgMVmoYi9cyVaeW4TqUWWWUzk-YOdU_hsgjeEHoVkRr-PaOb-gQ8JLXIUgNJRcCoz2UEhx1IZEjTXW4JRLX0rJhEwcqloOVXm2XaSUluUzdbEQzrp4gOISJ4VtPT5kgtWUZQdCitc-buyvTnj9AuvKRIqyie__OdL2CPBSZgScYPYXs5X7mXaGotqx7cKyZFD3YGg-G3If4eHZ-df-2FDxe9wFt_AO26JxU
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3batRA9FC3eHkRrbdo1REUH2xoMplMsoLIVlu2trsUaaFv42QuVbDZuhdkf8pv9Jxc1gahb33NTMLMuZ-cG8Dr2PmCJx7dVJ0VofDosxb0I987mzlvfeIMOYqjsRyeiC-n6eka_GlrYSitspWJlaC2E0P_yLe5RMoUMuXy48WvkKZGUXS1HaFRk8WBW_5Gl232Yf8z4vcN53u7x5-GYTNVIDSpTOahLnguczwZGtN51VINvQTvjXWRliI1keZkZQgvEp15LazjqZXa92WOppLTCX73BqyLBF2ZHqzv7I6Pvq7iFkj-oi3NyeX2DLWpoDgppT8g9Ye8o_6qKQH_64JLyrCbqHlJ8-3dg7uNycoGNY3dhzVXbsDNeojlcgNujZrw_AM4OpcDdj6xlH5UYfw9Q4GKX2VNqsFsiyEmSfIaN2V1FrqzzE4XZ4zqgymfdIlbLCuqypqHcHItwH0EvXJSuifAPE-0jXOPMsMK4_t9QyFEIbV1mdCmH0DcQlKZpp85jdX4qSq_Jpeqhr5C6KsK-ooH8G71zkXdzePK3TuEoNVO6sRdPZhMz1TD2AotzjTy3OVR4YSOpE7jwsYmShyqtMzFAbwl9CqSF3g8o5uyB7wkdd5SA0m1xWgmyAA2OzuRz013uSUQ1ciZmfrHFQG8Wi3Tm5Q7V7rJgvbwfoToSNMAHtf0tLpSklI_uTwPIOtQWufO3ZXyx_eqC3lOAdw0e3r1sV7C7eHx6FAd7o8PnsEdXrECD2OxCb35dOGeo0k3L140fMTg23Wz7l-RmVyH
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=m6A+modification%3A+recent+advances%2C+anticancer+targeted+drug+discovery+and+beyond&rft.jtitle=Molecular+cancer&rft.au=Deng%2C+Li-Juan&rft.au=Deng%2C+Wei-Qing&rft.au=Fan%2C+Shu-Ran&rft.au=Chen%2C+Min-Feng&rft.date=2022-02-14&rft.eissn=1476-4598&rft.volume=21&rft.issue=1&rft.spage=52&rft_id=info:doi/10.1186%2Fs12943-022-01510-2&rft_id=info%3Apmid%2F35164788&rft.externalDocID=35164788
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon